Page 23 - 80_04

Tratamientos experimentales contra el virus Ébola Zaire

Although neither a vaccine nor an effective antiviral treatment is currently
available for use in humans, the fundamental knowledge and experimental findings
already achieved, generate cautious optimism about the translation of these
findings into clinical practice for prevention and treatment of Ebola hemorrhagic
fever. However, it seems quite obvious that an effective progress will require
public financial support.

11. AGRADECIMIENTOS

La autora desea expresar su agradecimiento al Dr. J. C. Menéndez por la
elaboración de algunas de las figuras.

12. REFERENCIAS

1. Gatherer, D. The 2014 Ebola virus disease outbreak in West Africa. J. Gen. Virol. 95, 1619-
1624 (2014).

2. Feldmann, H.; Geisbert, T. W. Ebola haemorrhagic fever. Lancet, 377, 849-862 (2011).
3. Ver, por ejemplo: (a) Bray, M.; Davis, K.; Geisbert, T.; Schmaljohn, C.; Huggins; J. A mouse

model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis.
179, S248-58,(1999) (b) Bausch, D. G.; Sprecher, A. G.; Jeffs, B.; Boumandouki, P.
Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and
vaccines under outbreak conditions. Antiviral Res. 78, 150-161 (2008).
4. Gregory, S. M.; Harada, E.; Liang, B.; Delos, S. E.; White, J. M.; Tamm, L. K. Structure and
function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc. Natl.
Acad. Sci. U S A. 108, 11211-11216 (2011).
5. Gregory, S. M.; Larsson, P.; Nelson, E. A.; Kasson, P. M.; White, J. M.; Tamm, L. K. Ebolavirus
entry requires a compact hydrophobic fist at the tip of the fusion loop. J. Virol. 88, 6636-
6649 (2014).
6. (a) Carette, J. E.; Raaben, M.; Wong, A. C.; Herbert, A. S.; Obernosterer, G.; Mulherkar, N.;
Kuehne, A. I.; Kranzusch, P. J.; Griffin, A. M.; Ruthel, G.; Dal Cin, P.; Dye, J. M.; Whelan, S. P.;
Chandran, K.; Brummelkamp, T. R. Ebola virus entry requires the cholesterol transporter
Niemann–Pick C1. Nature 477, 340-343 (2011). (b) Côté, M.; Misasi, J.; Ren, T.; Bruchez, A.;
Lee, K.; Filone, C. M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; Cunningham, J. Small
molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature,
477, 344-348 (2011). (c) White, J. M.; Schornberg, K. L. A new player in the puzzle of
filovirus entry. Nat. Rev. Microbiol. 10, 317-322 (2012).
7. Chang, T.-Y.; Reid, P. C.; Sugii, S.; Ohgami, N.;Cruz, J. C.;. Chang, C. C. Y. Niemann-Pick Type C
Disease and Intracellular Cholesterol Trafficking. J. Biol. Chem. 280, 20917-20920 (2005).
8. Dhillon, R. S.; Srikrishna, D.; Sachs, J. Controlling Ebola: next steps Lancet 384, 1409-1411
(2014).
9. Kanapathipillai, R.; Restrepo, A. N. H.; Fast, P.; Wood, D.; Dye, Ch.; Kieny, M.-P.; Moorthy, V.
Ebola Vaccine-An Urgent International Priority. N. Eng. J. Med. DOI:
10.1056/NEJMp1412166 (2014).
10. Olinger, G. G.; Pettitt, J.; Kim, D.; Working, C.; Bohorov, O.; Bratcher, B.; Hiatt, E.; Hume, S. D.;
Jhonson, A. K.; Morton, J.; Pauly, M.; Whaley, K. J.; Lear, C. M.; Biggins, J. E.; Scully, C.;
Hensley, L.; Zeitlin, L. Delayed treatment of Ebola virus infection with plant-derived
monoclonal antibodies provides protection in rhesus machaques. Proc. Natl. Acad. Sci. U S
A. 109, 18030-18035 (2012).
11. Qiu, X.; Wong, G.; Audet, J.; Bello, A.; Fernando, L.; Alimonti, J. B.; Fausther-Bovendo, H.; Wei,
H.; Aviles, J.; Hiatt, E.; Jhonson, A.; Morton, J.; Swope, K.; Bohorov, O.; Bohorova, N.;
Goodman, C.; Kim, D.; Pauly, M. H.; Velasco, J.; Pettitt, J.; Olinger, G. G.; Whaley, K.; Xu, B.;
Strong, J. E.; Zeitlin, L.; Kobinger, G. P. Reversion of advanced Ebola virus disease in
nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
12. La empresa retiró este producto del mercado en octubre de 2011.

663